OncoLink at ASCO 2000: Monday, May 22 | Oncolink

Oncolink Features

Find My Cancer Drug

A Multicenter Randomized Phase III Study Comparing Paclitaxel-Cisplatin-Etoposide (TEP) Versus Cisplatin-Etoposide (EP) as Front - Line Treatment in Patients with Small Cell Lung Cancer (SCLC) Presenter: Dimitrios Mavroudis Affiliation: The Greek Lung Cancer Cooperative Group Background: The combination of etoposide (E) and cisplatin (P) is standard first line treatment for small cell lung cancer (SLSC). A complete response ...
A Phase III Trial of the Use of Long Term Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate. Presenter: Gerald E. Hanks Affiliation: Fox Chase Cancer Center Background: Radiation therapy is a long-standing treatment option for prostate cancer Previous studies by the RTOG and the EORTC have demonstrated improved disease-specific...
A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) Presenter: Joan H. Schulter Affiliation: ECOG Background: Since the initial randomized trials in the early 1990's which showed improved median and overall survival by adding chemotherapy to radiation therapy (RT) in NSCLC patients,...
A Randomized Trial Comparing Two Fractionation Schedules for Breast Irradiation Postlumpectomy in Node-Negative Breast Cancer Presenter: Timothy J. Whelan Affiliation: Hamilton Regional Cancer Ctr, Hamilton, ON, Canada; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Kingston Regional Cancer Ctr, Kingston, ON,...
Comparison of health-related quality of life (HRQOL) after brachytherapy, radical prostatectomy, or external beam radiation for localized prostate cancer Presenter: M.G. Sanda Affiliation: University of Michigan Background: Many oncologists believe that in selected patients, the differences between disease free survival and overall survival for radical prostatectomy (RP), external beam...
Cytoreduction Nephrectomy in Metastatic Renal Cancer: The Results of Southwest Oncology Group Trial 8949 Presenter: Robert Charles Flanigan Affiliation: Southwest Oncology Group Background: Metastatic renal cancer has a poor prognisis and is classically highly resistant to chemotherapy. A number of case series have reported a benefit to...
Postoperative Combined Radiation and Chemotherapy Improves Disease-Free Survival (DFS) and Overall Survival (OS) in Resected Adenocarcinoma of the Stomach and G.E. Junction. Results of Intergroup Study INT-0116 (SWOG 9008) Presenter: John S. Macdonald Affiliation: SWOG; ECOG; RTOG; CALGB; NCCTG Background: It is estimated that there will be 22,000 new cases and 13,500 deaths from gastric cancer in the US this year. The cure rate for gastric carcinoma...
Topotecan (T) vs. Observation (OB) Following Cisplatin (P) Plus Etoposide (E) in Extensive Stage Small Cell Lung Cancer (ES SCLC) (E7593): A Phase III Trial of the Eastern Cooperative Oncology Group (ECOG) Presenter: D. H. Johnson Affiliation: Vanderbilt University Background: Topotecan, a topoisomerase I inhibitor, has a 40% response rate as a first line agent in SCLC and moderate activity in chemoresistant SCLC. This Phase III trial...
Venlafaxine Alleviates Hot Flashes: An NCCTG Trial Presenter: Charles L Loprinzi Affiliation: North Central Cancer Treatment Group, Rochester, MN Background: Hot flashes can be a significant problem for many cancer patients. Unconventional treatments such as vitamin E and soy have been shown...